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1  | INTRODUC TION
Approximately 6000 living donor kidney transplantations are per‐
formed annually in the United States, comprising roughly 35% of 
the total volume of kidney transplantation. Laparoscopic donor 
nephrectomy (LDN) has become the preferred method for graft 
procurement due to decreased procedure‐related donor morbid‐
ity, shorter hospital stay, and faster return to work.1,2 This has ef‐
fectively doubled the donor kidney pool.3 Additionally, short‐ and 
long‐term graft function and survival have not been shown to 
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Abstract
Background: Intraoperative fluid management during laparoscopic donor nephrec‐
tomy (LDN) may have a significant effect on donor and recipient outcomes. We 
sought to quantify variability in fluid management and investigate its impact on donor 
and recipient outcomes.
Methods: A	retrospective	review	of	patients	who	underwent	LDN	from	July	2011	to	
January	2016	with	paired	kidney	recipients	at	a	single	center	was	performed.	Patients	
were divided into tertiles of intraoperative fluid management (standard, high, and 
aggressive). Donor and recipient demographics, intraoperative data, and postopera‐
tive outcomes were analyzed.
Results: Overall, 413 paired kidney donors and recipients were identified. 
Intraoperative fluid management (mL/h) was highly variable with no correlation to 
donor weight (kg) (R = 0.017). The aggressive fluid management group had signifi‐
cantly lower recipient creatinine levels on postoperative day 1. However, no signifi‐
cant differences were noted in creatinine levels out to 6 months between groups. No 
significant differences were noted in recipient postoperative complications, graft 
loss, and death. There was a significant increase (P < 0.01) in the number of total 
donor complications in the aggressive fluid management group.
Conclusions: Aggressive fluid management during LDN does not improve recipient 
outcomes and may worsen donor outcomes compared to standard fluid management.
K E Y W O R D S
fluid directed management, fluid status, intraoperative fluid management, laparoscopic donor 
nephrectomy, recipient outcomes
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differ significantly between recipients of the open and laparoscopic 
approaches.4
Despite the safety and benefits of LDN, there is no consen‐
sus regarding the intraoperative fluid management required to op‐
timize donor and recipient outcomes.5 While studies have shown 
that volume expansion with fluid administration can attenuate 
the adverse effects of pneumoperitoneum on renal hemodynam‐
ics,6,7 current research is inconclusive in characterizing the impact 
of pneumoperitoneum or volume expansion on early graft func‐
tion.4,8,9 In addition, much of the literature is outdated and based 
on animal models.7,9‐12 Furthermore, aggressive fluid management 
has been associated with adverse effects, including an increased 
risk of ileus, cardiopulmonary complications, and impaired wound 
healing.13,14 Despite this, many providers have held the view that 
fluid resuscitation during LDN may improve recipient outcomes. 
Thus, contemporary research investigating larger patient popula‐
tions is necessary to reach a consensus for both improved donor 
safety and recipient outcomes.
In this study, we sought to explore the relationship between in‐
traoperative fluid management during LDN and outcomes in donors 
and recipients. We hypothesized that intraoperative fluid manage‐
ment is highly variable, and that aggressive fluid management does 
not improve clinical outcomes compared to standard or high fluid 
management strategies.
2  | METHODS
2.1 | Ethical Considerations
The	protocol	was	reviewed	by	the	University	of	Michigan	Institutional	
Review Board (IRB) and was approved prior to initiation of the retro‐
spective review. The requirement for written‐informed consent was 
waived by the IRB.
2.2 | Hospital Setting
The	University	 of	Michigan	 is	 a	 1000‐bed	 tertiary	 care	 university	
hospital	located	in	Ann	Arbor,	Michigan	that	provides	inpatient	and	
outpatient	surgical	care	for	patients	in	Michigan	and	several	neigh‐
boring states. It is a high‐volume surgical center with a total of 66 
operating rooms where over 16 000 operations are performed each 
year.
2.3 | Study Population
A retrospective review of patients undergoing LDN, as well as adult 
recipients that underwent paired kidney transplantation, was per‐
formed	at	the	center	between	July	2011	and	January	2016.
Both donor and recipient parameters were collected, in‐
cluding age, gender, donor‐recipient relationship, and operative 
time. Additional donor demographics and perioperative char‐
acteristics	 included	weight,	 body	mass	 index	 (BMI),	 volume	 and	
rate of intraoperative fluid administration, estimated blood loss 
(EBL),	and	urine	output.	Postoperative	donor	outcomes	included	
donor length of stay (LOS), and need to receive diuretic ther‐
apy, either furosemide or mannitol. Additionally, recipient data 
were retrieved, including warm ischemia time (time between 
organ removal from ice to implantation), cold ischemia time (time 
on ice), and immunosuppression regimens. All recipients were 
ABO compatible and had a negative crossmatch (T and B cell). 
Postoperative	complications,	serial	creatinine	levels,	and	glomer‐
ular filtration rate (GFR) were also recorded. GFR was calculated 
using	the	Modification	of	Diet	in	Renal	Disease	(MDRD)	equation	
from serum creatinine, age, sex, and race.15 Graft and recipient 
survival were also compared.
After the data were retrieved, the relationship between rate 
(mL/h) of intraoperative fluid administration and donor weight (kg) 
was assessed. LDN patients were then divided into tertiles based 
on the type of intraoperative fluid management strategy (mL/kg/h) 
after adjusting for weight and time. Tertiles were chosen to fully 
assess fluid management strategies which reflected standard, high, 
and aggressive intraoperative fluid administration. Donor and recipi‐
ent demographics, intraoperative data, and postoperative complica‐
tions and outcomes were compared among groups.
2.4 | Intraoperative Care (LDN and Kidney 
Transplantation)
All LDN patients underwent similar intraoperative care as previously 
described.16	 Prior	 to	 arrival	 for	 surgery,	 LDN	patients	were	 asked	
to consume 10 oz. of a preoperative carbohydrate drink. No preop‐
erative hydration protocols were performed. Following anesthetic 
induction, LDN patients underwent ultrasound‐guided bilateral 
transversus	abdominus	plane	(TAP)	block.	Prior	to	incision,	specific	
fluid goals were discussed between anesthesia and surgical staff. In 
general, LDN patients were administered between 3‐5 L of lactated 
Ringer's (LR) solution intraoperatively. A mean arterial pressure of 
55 mm Hg or greater was targeted. Additional intravenous fluids 
were administered to achieve this goal based on anesthesiologist 
discretion and surgeon preference in concordance with EBL and 
renal vein compression or emptiness. Colloids were not routinely 
used, but may have been administered in patients with significant 
bleeding not requiring transfusion. None of the patients had invasive 
blood pressure monitoring. For kidney transplant recipients, 2‐4 L of 
LR was administered intraoperatively. Additional intravenous fluids 
were administered based on anesthesiologist discretion and surgeon 
preference.
2.5 | Operative Technique (LDN)
All patients underwent left LDN according to the original method pre‐
viously described.17 Briefly, the donor was placed in the right lateral de‐
cubitus position. A short‐periumbilical incision was made to expose the 
fascia in order to facilitate wound protector placement as a designated 
hand‐port.	Pneumoperitoneum	was	created	facilitating	12‐15	mm	Hg	
of insufflation. Two additional ports were placed in the left subcostal 
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region and mid‐abdomen to facilitate dissection. The left colon, spleen, 
and the tail of pancreas were mobilized medially. The splenorenal 
ligament was identified, and Gerota's fascia was mobilized from the 
spleen. The renal vein and artery, the adrenal vein, and the ureter were 
dissected and mobilized from their superior and lateral attachments. 
Lumbar veins were carefully identified and divided as needed. The dis‐
tal ureter was then secured with clips and divided, and the renal artery 
was stapled at its root with a vascular staple load. This was repeated 
with the renal vein. The kidney was then removed through the hand‐
assist port and immediately placed on ice and flushed with histidine‐
tryptophan‐ketoglutarate (HTK) solution.
2.6 | Operative Technique (Kidney Transplantation)
Recipients were placed on the operating room table in supine po‐
sition. A curvilinear right iliac fossa incision was made and carried 
down through the external and internal oblique muscles exposing 
the retroperitoneum. A fixed retractor was placed to expose the iliac 
vessels. The external iliac vein was clamped, and a venotomy was 
created. After flushing the vein with heparinized saline, the donor 
renal vein was anastomosed to the recipient iliac vein in an end‐to‐
side fashion. After clamping the external iliac artery, an arteriotomy 
was created and the artery irrigated with heparinized saline. The 
donor renal artery was then anastomosed to the recipient iliac artery 
in an end‐to‐side fashion. Finally, an external ureteroneocystostomy 
was performed using either the Lich technique or single U‐stitch 
technique.
2.7 | Postoperative Care (LDN and Kidney 
Transplant Recipients)
Postoperatively,	LDN	patients	were	involved	in	an	enhanced	recov‐
ery protocol.15 They were considered ready for discharge when their 
pain was controlled on oral medications and they were tolerating oral 
intake. Follow‐up was scheduled with the surgical team 2‐3 weeks 
after the operation.
For the first 24 hours postoperatively, kidney transplant recipi‐
ents underwent standardized urine replacement with 0.9% normal 
saline. When able to tolerate oral intake, they were instructed to 
drink 2 L/d of liquids. Kidney transplant recipients were deemed 
ready for discharge when they were tolerating oral intake, were 
able to take and manage their immunosuppressive medications, and 
had an improving renal function. Transplant immunosuppression in‐
volved primarily mycophenolate mofetil, tacrolimus, and steroids. 
Patient	was	seen	by	the	transplant	nephrology	team	serially	for	eval‐
uation of renal function.
2.8 | Endpoints
Primary	endpoints	involved	postoperative	short‐and	long‐term	cre‐
atinine levels and complications for both donors and recipients.
2.9 | Statistical Analyses
All	analyses	in	this	study	were	performed	using	GraphPad	Prism	ver‐
sion	6.00	 (GraphPad	Software;	San	Diego	CA).	Correlation	 testing	
was	performed	using	Pearson's	correlation	formula	with	R‐genera‐
tion. One‐way analysis of variance (ANOVA) for continuous varia‐
bles was performed between groups. Chi‐square testing was used to 
evaluate categorical variables between groups. Data are expressed 
as mean ± standard deviation (SD) unless specified otherwise. A P 
value < 0.05 was considered statistically significant.
3  | RESULTS
Overall, 413 patients who underwent LDN and their respective 
paired kidney transplant recipients were identified. In the LDN co‐
hort, intraoperative fluid management (mL/h) was highly variable 
with no correlation to donor weight (kg) (R = 0.017) (Figure 1).
Laparoscopic donor nephrectomy patients and their paired kid‐
ney recipients were divided into tertiles based on donor intraopera‐
tive standard (n = 138), high (n = 138), and aggressive (n = 137) fluid 
management rates (mL/kg/h). Following tertile division according 
to these intraoperative fluid management strategies, total volume 
of intraoperative fluid administration (mL: standard, 3618 ± 1006; 
high, 4624 ± 1124; aggressive, 5454 ± 1550; P < 0.001) and intra‐
operative fluid administration rates (mL/kg/h: standard, 14.8 ± 2.9; 
high, 23.1 ± 2.2; aggressive, 34.4 ± 7.3; P < 0.001) were significantly 
different among groups (Table 1).
3.1 | Donor
Significant differences (P < 0.05) in several donor demographics and 
intraoperative data were noted among fluid management groups 
(Table 1). Significant differences were observed in donor age (years: 
F I G U R E  1   Variability of Intraoperative Fluid Resuscitation. 
Intraoperative fluid resuscitation (mL/kg) with high variability with 
no correlation to donor weight (kg) (R = 0.017)
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standard, 45.1 ± 12.4; high, 40.3 ± 11.9; aggressive, 43.0 ± 11.7; 
P < 0.05), sex (male, %: standard, 51%; high, 35%; aggressive, 22%; 
P < 0.001), weight (kg: standard, 86.8 ± 15.9; high, 78.6 ± 12.9; ag‐
gressive, 68.4 ± 12.7; P	<	0.05),	and	BMI	(kg/m2: standard, 29.0 ± 4.2; 
high, 27.5 ± 4.7; aggressive, 24.6 ± 4.2; P < 0.05). Donors who re‐
ceived aggressive fluid management were noted to have significantly 
higher rates of intraoperative urine output compared to those who 
received standard fluid management (urine output, mL/kg/h: stand‐
ard, 14.8 ± 3.0; high, 23.1 ± 2.15; aggressive, 24.4 ± 7.3; P < 0.001). 
Operative time was noted to be significantly longer in the standard 
fluid management group compared to the high and aggressive fluid 
management groups (operative time, minutes: standard, 171 ± 28.5; 
high, 154 ± 29.7; aggressive, 141 ± 31.3; P < 0.05). A significantly 
higher number of patients received furosemide in the aggressive fluid 
 Normal (N = 138) High (N = 138)
Aggressive 
(N = 137) P‐Value
Demographic data
Age (y) 45.1 ± 12.4 40.3 ± 11.9 43.0 ± 11.7 <0.05
Sex (n, %)
Male 70 (51%) 47 (35%) 30 (22%) <0.001
Female 68 (49%) 91 (65%) 107 (78%)
Race
White 108 (78%) 105 (76%) 107 (78%) 0.89
Black 18 (13%) 11 (8%) 6 (4%)
Asian 1 (1%) 2 (1%) 6 (4%)
Other 11 (8%) 20 (15%) 18 (14%)
Relationship to recipient
Living related 69 (50%) 68 (49%) 62 (45%) 0.75
Living 
unrelated
55 (40%) 56 (41%) 60 (44%)
Unknown 14 (10%) 14 (10%) 15 (11%)
Weight (kg) 86.8 ± 15.9 78.6 ± 12.9 68.4 ± 12.7 <0.001
BMI	(kg/m2) 29.0 ± 4.2 27.5 ± 4.7 24.6 ± 4.2 <0.05
Intraoperative data
Total fluid 
volume (mL)
3618 ± 1006 4624 ± 1124 5454 ± 1550 <0.001
Total fluid rate 
(mL/kg/h)
14.8 ± 2.9 23.1 ± 2.2 34.3 ± 7.3 <0.001
Estimated 
blood loss 
(mL)
73.3 ± 109.1 55.4 ± 80.7 101.3 ± 250.1 0.64
Urine output 
(mL)
468.8 ± 387.4 787.9 ± 626.6 984.4 ± 1089 <0.001
Urine output 
(mL/kg/h)
14.8 ± 3.0 23.1 ± 2.15 34.4 ± 7.3 <0.001
Operative time 
(min)
171.6 ± 28.5 154 ± 29.7 141.9 ± 31.3 <0.05
Patients	
receiving 
furosemide  
(n, %)
2 (1.4%) 13 (9.4%) 26 (19%) <0.001
Patients	
receiving 
mannitol  
(n, %)
53 (38.4%) 49 (35.5%) 51 (37.2%) 0.88
Postoperative	outcomes
Length of stay 
(d)
1.72 ± 0.8 1.89 ± 0.9 1.91 ± 0.8 0.12
Data are expressed as mean ± SD or count (percentage).
TA B L E  1   Donor demographics, 
intraoperative data, and postoperative 
outcomes
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management group compared to other groups (%: standard, 1.4%; high, 
9.4%; aggressive, 19%; P < 0.001).
Significant differences (P < 0.05) were also noted in several post‐
operative donor outcomes among fluid management groups. Donor 
LOS was longer in the aggressive fluid management group (days; ag‐
gressive, 1.91 ± 0.8; standard, 1.72 ± 0.8), although this was not statis‐
tically significant (P = 0.13) (Table 1). However, there was a significant 
increase in the number of total postoperative complications in the 
aggressive fluid management group compared to other groups (total 
complications; standard, 0 [0%]; high, 2 [1.45%]; aggressive, 15 [10.9%]; 
P < 0.01) (Table 2). Specifically, the number of patients that had pro‐
longed hospitalization (>7 days) and incisional hernia was significantly 
higher (P < 0.05) in the aggressive fluid management group compared 
to the standard fluid management group. No significant differences 
were observed in creatinine levels at baseline, 30 days, and 90 days 
following LDN between fluid management groups (Table 3).
3.2 | Recipient
No significant differences were noted in recipient demographics 
and intraoperative data, including warm and cold ischemia times 
(Table 4). No significant differences were noted in immunosuppres‐
sion regimens between groups.
The aggressive fluid management group had a significantly 
lower average creatinine level on postoperative day 1 compared to 
other groups (Cr, postoperative day 1; standard, 3.68 ± 2.0; high, 
3.74 ± 2.2; aggressive, 3.15 ± 1.9; P < 0.05) (Table 3). However, no 
significant differences were noted in subsequent creatinine levels 
at 30 days, 90 days, and 6 months following transplantation among 
groups. In addition, no significant differences were noted in recipi‐
ent postoperative complications, including acute rejection and de‐
layed graft function, graft loss, and recipient death at 1 and 2 years 
following transplantation (Tables 5 and 6).
4  | DISCUSSION
In this study, we sought to quantify the variability in intraoperative 
fluid management during LDN and investigate the effects of fluid 
management strategies on donor and recipient outcomes. Several 
key findings were noted. First, intraoperative fluid management was 
highly variable with no correlation to donor weight. Second, LDN 
patients in the aggressive fluid management group had significantly 
more total complications compared to other fluid management 
groups; there was also a trend toward a longer LOS for those who 
received aggressive fluid management. Third, donor patients who 
received aggressive fluid management had paired kidney recipients 
with a significantly decreased early creatinine level at postoperative 
day 1; however, no differences were observed in creatinine levels at 
any subsequent postoperative time points up to 6 months between 
groups. Lastly, no significant differences were noted in recipient 
complications, and graft and recipient survival among fluid manage‐
ment groups.
Within the last two decades, LDN has become the mainstay 
technique of living donor kidney transplantation. The laparoscopic 
approach, compared to open technique, has afforded decreased 
donor complications and postoperative pain, as well as a shorter 
hospital stay and quicker return to work.1,2 A potential threat follow‐
ing the laparoscopic approach, however, is an increased theoretical 
risk to the donor kidney secondary to pneumoperitoneum. When 
an insufflation pressure of 12‐15 mm Hg is achieved, pneumoperi‐
toneum can be associated with a decrease in renal blood flow and 
subsequently worse renal function.18 In the short term, this may 
affect early renal function following transplantation.19 However, in 
the long‐term, no differences in renal function have been noted be‐
tween open donor nephrectomy (ODN) and LDN at 1 year following 
surgery.20 Nevertheless, the clinical significance of these findings is 
largely to be determined.
Controversy exists regarding fluid management and the opti‐
mal fluid balance in the perioperative period. Numerous intraoper‐
ative fluid management strategies, including restrictive and liberal, 
have been proposed. However, both have their benefits and risks. 
Liberal intraoperative fluid management may lead to poor wound 
healing, postoperative ileus, as well as fluid overload contributing 
to heart and pulmonary failure.13,14,21 Restrictive fluid management, 
however, may result in hypovolemia, inadequate organ perfusion, 
and postoperative symptoms including nausea and vomiting.21,22 
Similarly, there are various propositions regarding the benefits of 
these strategies. Some studies demonstrate benefit from liberal fluid 
resuscitation intraoperatively, 22,23 while others demonstrate no 
 
Standard 
(N = 138) High (N = 138)
Aggressive 
(N = 137) P‐Value
Prolonged	hospitalization	
(>7 d)
0 (0%)*  0 (0%)*  4 (2.9%)*  <0.05
Renal dysfunction 0 (0%) 1 (0.7%) 2 (1.5%) 0.37
Wound infection 0 (0%) 1 (0.7%) 4 (2.9%) 0.08
Incisional hernia 0 (0%)*  0 (0%)*  4 (2.9%)*  <0.05
Reoperation 0 (0%) 0 (0%) 1 (0.7%) 0.37
Total 0 (0%)*  2 (1.45%)*  15 (10.9%)*  <0.01
Data are expressed as count (percentage). Renal dysfunction defined as CrCl <50 cc/min.
*Designates P < 0.05 between normal and aggressive and high and aggressive groups. 
TA B L E  2   Donor complications at 
1 year following donor nephrectomy
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difference in outcomes.25 However, optimal fluid management strat‐
egies in the perioperative period remain a matter of investigation.
Only a few studies have been conducted to determine the op‐
timal fluid management strategies in patients undergoing both 
LDN and ODN. Initial studies focused on attenuating the effects of 
pneumoperitoneum on renal blood flow, creatinine, and urine out‐
put	using	crystalloid	and	colloid	resuscitation.	Mertens	zur	Borg	et	
al randomized patients undergoing LDN to three fluid management 
strategies: (a) crystalloids administered overnight, at induction, 
and before pneumoperitoneum; (b) crystalloids administered over‐
night and a colloid bolus at induction and before pneumoperito‐
neum; and (c) aggressive crystalloid infusion during the operation.26 
Preoperative	crystalloids	with	colloid	administration	demonstrated	
higher donor stroke volume and increased urine output during LDN 
compared to those receiving aggressive intraoperative crystalloid 
infusions.26 However, follow‐up studies comparing preoperative 
crystalloids with colloid administration at the onset of induction and 
during pneumoperitoneum demonstrated similar hemodynamics, 
urine output, creatinine, graft survival, and recipient survival be‐
tween LDN and ODN patients.27
Studies have also compared intraoperative fluid management 
strategies during LDN alone. In a prospective study with retrospec‐
tive augmentation, Bergman et al assessed patients receiving high 
fluid rates (>10 mL/kg/h) and fluid‐restricted rates (<10 mL/kg/h) 
during LDN.8 Although LDN patients subjected to intraoperative 
fluid‐restriction had lower intraoperative urine output, no significant 
differences were observed in recipient postoperative creatinine up 
to 12 months, delayed graft function, or acute rejection between 
 
Standard 
(N = 138) High (N = 138)
Aggressive 
(N = 137) P‐Value
Donor
Cr,	Preop 1.19 (0.27) 1.18 (0.25) 1.15 (0.24) 0.40
GFR,	Preop 64.5 (14.8) 61.9 (13.1) 63.1 (15.4) 0.56
Cr, 30 d 1.20 (0.30) 1.21 (0.22) 1.16 (0.24) 0.40
Cr, 90 d 1.19 (0.25) 1.18 (0.23) 1.17 (0.24) 0.50
Recipient
Cr,	Postop	Day	1 3.68 (2.0)*  3.74 (2.2)*  3.15 (1.9)*  <0.05
Cr, 30 d 1.46 (0.50) 1.49 (0.63) 1.47 (0.60) 0.89
Cr, 90 d 1.43 (0.60) 1.35 (0.38) 1.38 (0.43) 0.40
Cr,	6	Mo 1.41 (0.65) 1.34 (0.37) 1.37 (0.42) 0.37
Creatinine (Cr) listed as mg/dL. Glomerular function rates (GFR) listed as mL/min/1.73 m2. Data are 
expressed as mean ± SD or count (percentage).
*Designates P < 0.05 between normal and aggressive and high and aggressive groups. 
TA B L E  3   Creatinine levels before and 
after surgery
 Normal (N = 138) High (N = 138)
Aggressive 
(N = 137) P‐Value
Demographics
Age (y) 45.1 ± 12.4 40.3 ± 11.9 43.0 ± 11.7 0.06
Intraoperative Data
Warm ischemia time 
(min)
33.6 ± 10.2 31.8 ± 8.2 33.0 ± 11.6 0.43
Cold ischemia time 
(min)
124.4 ± 70.8 128.7 ± 64 130.3 ± 71.5 0.63
Immunosuppression
Tacrolimus 138 (100%) 135 (97.8%) 135 (98.5%) 0.22
Mycophenolate	
mofetil
123 (89.1%) 127 (92%) 130 (94.7%) 0.31
mycophenolate 
sodium
19 (13.7%) 22 (15.9%) 24 (17.5%) 0.71
Cyclosporine 1 (0.7%) 0 (0%) 0 (0%) 0.37
Everolimus 4 (2.9%) 5 (3.6%) 8 (5.8%) 0.45
Data are expressed as mean ± SD or count (percentage). Warm ischemia time defined as time from 
organ removal from ice to implantation.
TA B L E  4   Recipient demographics, 
intraoperative data, and 
immunosuppression
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groups.8 Although prospective, the study had several limitations in‐
cluding a limited number of patients per group (<30 patients). Our 
study, however, is the largest study (>130 patients per group) eval‐
uating fluid management strategies during LDN and their impact on 
donor and recipient outcomes.
To fully assess different fluid management strategies, we chose 
to divide our LDN cohort into three groups, which allowed assess‐
ment of three fluid management strategies including standard, high, 
and aggressive fluid administration. These terms were decided after 
consultation and data interpretation with our expert anesthesiology 
colleagues. The findings of this study demonstrate that aggressive 
fluid management during LDN does not improve recipient outcomes 
compared to standard intraoperative fluid management. Although 
early differences in creatinine levels were observed at postoperative 
day 1, no significant differences were observed at subsequent time 
points up to 6 months. This is consistent with other studies.8,26,27 
Furthermore, no significant differences were observed in recipi‐
ent postoperative complications, graft loss, and death among fluid 
management groups. However, we did observe several potential ad‐
verse events that can be associated with aggressive intraoperative 
fluid management during LDN. The aggressive fluid management 
group had a significantly higher number of total complications in 
donor patients, including prolonged hospitalization (>7 days) sec‐
ondary to cardiopulmonary issues and incisional hernia, compared 
to other fluid management groups. We suspect that the increased 
edema and incisional tension from aggressive fluid management may 
be responsible for the increased rate of hernia. Although not statis‐
tically different, there was also a trend toward prolonged LOS in the 
aggressive fluid management group.
We also had some unexpected significant differences among 
donor demographics and intraoperative characteristics. Significant 
differences were noted in age and gender among fluid management 
groups. The standard fluid management group was significantly 
older than the high fluid management group; however, no significant 
difference in age was noted when compared with the aggressive 
fluid	management	group.	Male	predominance	was	also	noted	in	the	
 Low (N = 138) Medium (N = 138) High (N = 137) P‐Value
Cancer 0 (0) 1 (0.7%) 2 (1.5%) 0.36
Diabetes mellitus 5 (3.6%) 9 (6.5%) 7 (5.1%) 0.54
Bacterial infection 18 (13%) 15 (10.1%) 16 (11.7%) 0.85
Viral Infection
BK infection 9 (6.5%) 6 (4.3%) 16 (11.7%) 0.07
Other 3 (2.1%) 6 (4.3%) 7 (5.1%) 0.42
Major	cardiac	event 6 (4.3%) 3 (2.2%) 2 (1.5%) 0.29
Transfusion 7 (5.1%) 5 (3.6%) 12 (8.8%) 0.17
Acute rejection 20 (14.5%) 26 (18.8%) 19 (13.9%) 0.47
Delayed graft 
function
2 (1.5%) 1 (1.5%) 1 (1.5%) 0.99
Ureteral leak 1 (0.7%) 0 (0%) 0 (0%) 0.63
Ureteral stricture 1 (0.7%) 1 (0.7%) 1 (0.7%) 0.99
Vascular thrombosis 1 (0.7%) 1 (0.7%) 0 (0%) 0.63
Wound infection/
dehiscence
2 (1.5%) 0 (0%) 0 (0%) 0.15
Total 86 (62.3%) 84 (61%) 83 (60%) 0.83
Data are expressed as mean ± SD or count (percentage).
TA B L E  5   Recipient postoperative 
complications at 1 year following 
transplant
 
Standard 
(N = 138) High (N = 138)
Aggressive 
(N = 137) P‐Value
Graft loss 7 (5.1%) 12 (8.7%) 12 (8.8%) 0.39
1‐year graft loss 3 (2.2%) 2 (1.5%) 3 (2.2%) 0.87
2‐year graft loss 3 (2.2%) 3 (2.2%) 5 (3.6%) 0.69
Recipient death 3 (2.2%) 3 (2.2%) 2 (1.5%) 0.87
1‐year recipient 
death
3 (2.2%) 1 (0.7%) 2 (1.5%) 0.60
2‐year recipient 
death
3 (2.2%) 3 (2.2%) 2 (1.5%) 0.88
Data are expressed as count (percentage).
TA B L E  6   Graft loss and recipient death
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standard fluid management group. However, we do not believe that 
this significantly affected the outcomes of our study. In addition, 
we	noted	higher	donor	weight	(kg),	BMI,	and	operative	time	in	our	
standard fluid management group compared to the aggressive fluid 
management	group.	The	increased	weight	and	BMI	likely	translated	
into longer operative times for the standard fluid management group 
due to operative complexities.
Overall, the findings of this study highlight that, contrary to prior 
belief, aggressive fluid management during LDN does not appear to 
impact outcomes in transplant recipients. As aggressive fluid man‐
agement can be potentially deleterious to the donor and may gen‐
erate problems, as shown in this study, attaining normal fluid status 
during	LDN	appears	to	be	a	beneficial	prospect.	Patient‐tailored	re‐
suscitation may be the ideal approach, and future prospective, ran‐
domized control trials studies are required to further confirm these 
recommendations. Although we did not use these in our study, non‐
invasive methods like esophageal Doppler and inflatable finger cuffs 
are available and may help achieve a patient‐tailored resuscitative 
approach perioperatively. Further studies are required to generate 
data to support their use.
This study has several limitations. First, this is a retrospective 
review, which may limit its clinical translation. However, these 
findings prompt future work in providing safe and effective care 
of healthy donors. This will require prospective studies and ran‐
domized trials to better assess the role of donor intraoperative 
fluid management on clinical outcomes. Second, this study has 
several confounding factors, as several significant differences 
were found among donor groups. Although we do not feel this sig‐
nificantly affects our conclusions, it may affect postoperative out‐
comes. Third, some aspects of clinical data, including both donor 
and recipient data (immunosuppressive induction agents, pre‐ and 
postoperative fluid status, postoperative pain levels, etc), were 
difficult to obtain via chart review and are not included. Fourth, 
fluid management strategies were divided into tertiles, including 
“standard,” “high,” and “aggressive” fluid management groups, 
after consultation with anesthesiology colleagues; this was based 
on the historic context that higher fluid management strategies 
may improve recipient outcomes. However, we recognize that 
standard fluid management in this study may be higher than typi‐
cal intraoperative fluid management for other operative cases and 
this is clearly a limitation. Fifth, patients in the donor cohort had 
mean estimated GFRs <70 mL/min in all three groups. We suspect 
this	was	secondary	to	the	MDRD	underestimating	the	GFR,	which	
can occur by up to 29% in healthy individuals.28 Our institution 
has an acceptable GFR minimum of 60 mL/min. Although these 
donor GFRs were lower than expected, there were no significant 
differences in GFR among groups. However, this may affect the 
generalizability of our results. Sixth, although creatinine is an 
important marker of renal function, we recognize that there are 
superior markers of acute renal function and ischemia, including 
neutrophil gelatinase‐associated lipocalin (NGAL); however, eval‐
uating these markers was beyond the scope of this study. Seventh, 
fluid management strategies from this data set were based on the 
historic context that aggressive fluid management may improve 
recipient outcomes; although we were unable to assess restrictive 
fluid management strategies in this study, we plan to assess it in 
future studies. Eighth, this study is limited to a single institution; 
future work will involve prospective studies across multiple insti‐
tutions with inclusion of larger patient cohorts to determine opti‐
mal fluid resuscitation during LDN.
5  | CONCLUSIONS
In conclusion, fluid management strategies during LDN remain 
highly variable and may have significant effects on donor and recipi‐
ent outcomes. Although aggressive fluid management during LDN 
may decrease early creatinine levels in recipients, it does not ap‐
pear to have any significant effects on long‐term creatinine levels, 
postoperative complications, or graft survival. However, aggressive 
fluid management may increase the risk for postoperative complica‐
tions and prolong hospitalization for donor patients following LDN. 
Further work is required to help construct guidelines to help further 
optimize fluid management during LDN.
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